Mankind Pharma Q3 Profit Jumps 9.5% to Rs 414 Cr, Driven by Domestic Growth

• Mankind Pharma reported a 9.5% increase in consolidated profit after tax (PAT) to Rs 414 crore for the December quarter.
• The company's revenue from operations rose to Rs 3,567 crore, up from Rs 3,199 crore in the same period last year.
• Domestic market revenue reached Rs 3,046 crore, marking an 11% increase from the previous year.
• Vice Chairman & MD Rajeev Juneja highlighted four key pillars for sustained growth: steady base business, specialty chronic, OTC business, and super specialty BSV portfolio.
• Shares of Mankind Pharma closed 4.3% higher at Rs 2,155.90 apiece on BSE following the announcement.

Why It Matters: Mankind Pharma's Q3 profit surged by 9.5% to Rs 414 crore, primarily fueled by robust domestic market performance.